Transforming growth factor-β1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium

Anna Benetti, Angiola Berenzi, Marco Gambarotti, Emirena Garrafa, Maurizio Gelati, Enrico Dessy, Nazario Portolani, Tullio Piardi, Stefano Maria Giulini, Arnaldo Caruso, Gloria Invernici, Eugenio Agostino Parati, Roberto Nicosia, Giulio Alessandri

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of most malignant and aggressive human tumors. Transforming growth factor-β1 (TGF-β1) and its coreceptor CD105 have been shown to contribute to HCC malignant progression. TGF-β1 and CD105 have also been implicated in angiogenesis, but their role in the vascularization of HCC has not been investigated. To fill this gap, we studied the effect of TGF-β1 and CD105 on HCC-derived endothelium. By using immunomagnetic beads, we isolated and cultured endothelial cells (ECs) from HCC (HCC-EC) and adjacent nonneoplastic tissue (nNL-ECs) obtained from 24 liver biopsies. HCC and nNL biopsies were also analyzed by immunohistochemistry for the expression of CD105, TGF-β1, Ve-cadherin (Ve-cad), CD44, β-catenin, and E-cadherin. Compared with nNL-ECs, HCC-ECs had higher expression of CD105, enhanced spontaneous motility, and greater capacity to migrate in response to TGF-β1 (5ng/mL), particularly in the presence of a fibronectin matrix. The chemotactic effect of TGF-β1 was blocked by anti-CD105 antibodies and correlated with the grade of HCC malignancy. Histologic examination of HCC biopsies showed that HCCs with the worse malignant features had the highest expression of TGF-β1, CD105, and angiogenic markers (Ve-cad and CD44). Because CD105 was highly expressed in microvessels at the tumor periphery and TGF-β1 staining was only found in neoplastic hepatocytes, we conclude that HCC-derived TGF-β1 may act as a chemoattractant for CD105-expressing ECs and as a promoter of tumor angiogenesis. Thus, drugs that selectively target the TGF-β-1/CD105 axis may interfere with HCC-related angiogenesis and HCC progression.

Original languageEnglish
Pages (from-to)8626-8634
Number of pages9
JournalCancer Research
Volume68
Issue number20
DOIs
Publication statusPublished - Oct 15 2008

Fingerprint

Transforming Growth Factors
Endothelium
Hepatocellular Carcinoma
Endothelial Cells
Cadherins
Biopsy
Catenins
Neoplasms
Chemotactic Factors
Microvessels
Fibronectins
Carcinogens
Anti-Idiotypic Antibodies
Hepatocytes
Cultured Cells
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Transforming growth factor-β1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. / Benetti, Anna; Berenzi, Angiola; Gambarotti, Marco; Garrafa, Emirena; Gelati, Maurizio; Dessy, Enrico; Portolani, Nazario; Piardi, Tullio; Giulini, Stefano Maria; Caruso, Arnaldo; Invernici, Gloria; Parati, Eugenio Agostino; Nicosia, Roberto; Alessandri, Giulio.

In: Cancer Research, Vol. 68, No. 20, 15.10.2008, p. 8626-8634.

Research output: Contribution to journalArticle

Benetti, A, Berenzi, A, Gambarotti, M, Garrafa, E, Gelati, M, Dessy, E, Portolani, N, Piardi, T, Giulini, SM, Caruso, A, Invernici, G, Parati, EA, Nicosia, R & Alessandri, G 2008, 'Transforming growth factor-β1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium', Cancer Research, vol. 68, no. 20, pp. 8626-8634. https://doi.org/10.1158/0008-5472.CAN-08-1218
Benetti, Anna ; Berenzi, Angiola ; Gambarotti, Marco ; Garrafa, Emirena ; Gelati, Maurizio ; Dessy, Enrico ; Portolani, Nazario ; Piardi, Tullio ; Giulini, Stefano Maria ; Caruso, Arnaldo ; Invernici, Gloria ; Parati, Eugenio Agostino ; Nicosia, Roberto ; Alessandri, Giulio. / Transforming growth factor-β1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. In: Cancer Research. 2008 ; Vol. 68, No. 20. pp. 8626-8634.
@article{bd47b04a994d46d499c5e640fdbf8307,
title = "Transforming growth factor-β1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium",
abstract = "Hepatocellular carcinoma (HCC) is one of most malignant and aggressive human tumors. Transforming growth factor-β1 (TGF-β1) and its coreceptor CD105 have been shown to contribute to HCC malignant progression. TGF-β1 and CD105 have also been implicated in angiogenesis, but their role in the vascularization of HCC has not been investigated. To fill this gap, we studied the effect of TGF-β1 and CD105 on HCC-derived endothelium. By using immunomagnetic beads, we isolated and cultured endothelial cells (ECs) from HCC (HCC-EC) and adjacent nonneoplastic tissue (nNL-ECs) obtained from 24 liver biopsies. HCC and nNL biopsies were also analyzed by immunohistochemistry for the expression of CD105, TGF-β1, Ve-cadherin (Ve-cad), CD44, β-catenin, and E-cadherin. Compared with nNL-ECs, HCC-ECs had higher expression of CD105, enhanced spontaneous motility, and greater capacity to migrate in response to TGF-β1 (5ng/mL), particularly in the presence of a fibronectin matrix. The chemotactic effect of TGF-β1 was blocked by anti-CD105 antibodies and correlated with the grade of HCC malignancy. Histologic examination of HCC biopsies showed that HCCs with the worse malignant features had the highest expression of TGF-β1, CD105, and angiogenic markers (Ve-cad and CD44). Because CD105 was highly expressed in microvessels at the tumor periphery and TGF-β1 staining was only found in neoplastic hepatocytes, we conclude that HCC-derived TGF-β1 may act as a chemoattractant for CD105-expressing ECs and as a promoter of tumor angiogenesis. Thus, drugs that selectively target the TGF-β-1/CD105 axis may interfere with HCC-related angiogenesis and HCC progression.",
author = "Anna Benetti and Angiola Berenzi and Marco Gambarotti and Emirena Garrafa and Maurizio Gelati and Enrico Dessy and Nazario Portolani and Tullio Piardi and Giulini, {Stefano Maria} and Arnaldo Caruso and Gloria Invernici and Parati, {Eugenio Agostino} and Roberto Nicosia and Giulio Alessandri",
year = "2008",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-08-1218",
language = "English",
volume = "68",
pages = "8626--8634",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Transforming growth factor-β1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium

AU - Benetti, Anna

AU - Berenzi, Angiola

AU - Gambarotti, Marco

AU - Garrafa, Emirena

AU - Gelati, Maurizio

AU - Dessy, Enrico

AU - Portolani, Nazario

AU - Piardi, Tullio

AU - Giulini, Stefano Maria

AU - Caruso, Arnaldo

AU - Invernici, Gloria

AU - Parati, Eugenio Agostino

AU - Nicosia, Roberto

AU - Alessandri, Giulio

PY - 2008/10/15

Y1 - 2008/10/15

N2 - Hepatocellular carcinoma (HCC) is one of most malignant and aggressive human tumors. Transforming growth factor-β1 (TGF-β1) and its coreceptor CD105 have been shown to contribute to HCC malignant progression. TGF-β1 and CD105 have also been implicated in angiogenesis, but their role in the vascularization of HCC has not been investigated. To fill this gap, we studied the effect of TGF-β1 and CD105 on HCC-derived endothelium. By using immunomagnetic beads, we isolated and cultured endothelial cells (ECs) from HCC (HCC-EC) and adjacent nonneoplastic tissue (nNL-ECs) obtained from 24 liver biopsies. HCC and nNL biopsies were also analyzed by immunohistochemistry for the expression of CD105, TGF-β1, Ve-cadherin (Ve-cad), CD44, β-catenin, and E-cadherin. Compared with nNL-ECs, HCC-ECs had higher expression of CD105, enhanced spontaneous motility, and greater capacity to migrate in response to TGF-β1 (5ng/mL), particularly in the presence of a fibronectin matrix. The chemotactic effect of TGF-β1 was blocked by anti-CD105 antibodies and correlated with the grade of HCC malignancy. Histologic examination of HCC biopsies showed that HCCs with the worse malignant features had the highest expression of TGF-β1, CD105, and angiogenic markers (Ve-cad and CD44). Because CD105 was highly expressed in microvessels at the tumor periphery and TGF-β1 staining was only found in neoplastic hepatocytes, we conclude that HCC-derived TGF-β1 may act as a chemoattractant for CD105-expressing ECs and as a promoter of tumor angiogenesis. Thus, drugs that selectively target the TGF-β-1/CD105 axis may interfere with HCC-related angiogenesis and HCC progression.

AB - Hepatocellular carcinoma (HCC) is one of most malignant and aggressive human tumors. Transforming growth factor-β1 (TGF-β1) and its coreceptor CD105 have been shown to contribute to HCC malignant progression. TGF-β1 and CD105 have also been implicated in angiogenesis, but their role in the vascularization of HCC has not been investigated. To fill this gap, we studied the effect of TGF-β1 and CD105 on HCC-derived endothelium. By using immunomagnetic beads, we isolated and cultured endothelial cells (ECs) from HCC (HCC-EC) and adjacent nonneoplastic tissue (nNL-ECs) obtained from 24 liver biopsies. HCC and nNL biopsies were also analyzed by immunohistochemistry for the expression of CD105, TGF-β1, Ve-cadherin (Ve-cad), CD44, β-catenin, and E-cadherin. Compared with nNL-ECs, HCC-ECs had higher expression of CD105, enhanced spontaneous motility, and greater capacity to migrate in response to TGF-β1 (5ng/mL), particularly in the presence of a fibronectin matrix. The chemotactic effect of TGF-β1 was blocked by anti-CD105 antibodies and correlated with the grade of HCC malignancy. Histologic examination of HCC biopsies showed that HCCs with the worse malignant features had the highest expression of TGF-β1, CD105, and angiogenic markers (Ve-cad and CD44). Because CD105 was highly expressed in microvessels at the tumor periphery and TGF-β1 staining was only found in neoplastic hepatocytes, we conclude that HCC-derived TGF-β1 may act as a chemoattractant for CD105-expressing ECs and as a promoter of tumor angiogenesis. Thus, drugs that selectively target the TGF-β-1/CD105 axis may interfere with HCC-related angiogenesis and HCC progression.

UR - http://www.scopus.com/inward/record.url?scp=54249139202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54249139202&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-1218

DO - 10.1158/0008-5472.CAN-08-1218

M3 - Article

VL - 68

SP - 8626

EP - 8634

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 20

ER -